Multiple myeloma (MM) is a plasma cell neoplasm that commonly expresses CD38.
Daratumumab (DARA), a human monoclonal antibody targeting CD38, has significantly …

Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface
receptor CD38, which is expressed not only on plasma cells but also on NK cells and …

Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated
clinical activity and a manageable safety profile in monotherapy and combination therapy …

Daratumumab (Dara), a human immunoglobulin G1 kappa (IgG1κ) monoclonal anti-CD38
antibody, has been approved by the US Food and Drug Administration for the treatment of …

Daratumumab targets CD38-expressing myeloma cells through a variety of immune-
mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell …

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the
treatment of multiple myeloma (MM). Although recent data have demonstrated very …

Emerging evidence suggests that FcγR-mediated cross-linking of tumor-bound mAbs may
induce signaling in tumor cells that contributes to their therapeutic activity. In this study, we …

Anti-CD38 monoclonal antibody (MoAb) treatments including daratumumab (DARA) are
effective therapies for both newly diagnosed and relapsed multiple myeloma (MM). In this …

CD38, a type II transmembrane glycoprotein highly expressed in hematological
malignancies including multiple myeloma (MM), represents a promising target for mAb …

Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on
multiple myeloma cells. The aim of this study was to investigate the clinical implications and …